Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features
NCT04028466 · St. Luke's Medical Center, Philippines · PHASE4 · terminated · last registry update 2023-11-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Budget for the study was withdrawn and discontinued” | – | Registry record, St. Luke's Medical Center, Philippines |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ATP4A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-30Results posted on the registry: Eli Lilly and Company, Selpercatinib + Ranitidine (NCT05338502)
- 2024-09-27Results posted on the registry: Pfizer, losartan + dextromethorphan (NCT03864042)
- 2024-09-26Results posted on the registry: Takeda, Maribavir Commercial Tablet Formulation + Maribavir Pediatric Powder-for-oral Suspension Formulation (NCT05918822)
- 2024-09-23Results posted on the registry: Clinic for Psychiatric Disorders, Dr Laza Lazarevic, Aspirin + Placebo (NCT02685748)
- 2024-09-19Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Classic quadruple therapy + Quadruple therapy with sodium bicarbonate instead of bismuth (NCT06591494)
- 2024-08-29Phase 3 first posted: Alexandria University, Vonoprazan + Amoxicillin (NCT06576882)
- 2024-08-15Results posted on the registry: Daniel Freedberg, MD, Omeprazole 40 mg bid (NCT01901276)
- 2024-08-15Results posted on the registry: R-Pharm International, LLC, Olokizumab + Omeprazole (NCT04246762)
- 2024-08-01Phase 3 first posted: The University of Texas Health Science Center, Houston, Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days + Protonix (pantoprazole) 40 mg q 24 hrs for 2 days (NCT06531642)
- 2024-06-03Results posted on the registry: Phathom Pharmaceuticals, Inc., Vonoprazan (NCT05343364)
- 2024-05-01Phase 3 first posted: Ottawa Hospital Research Institute, Omeprazole 20 mg Oral Tablet (NCT06393868)
- 2024-04-01Phase 3 first posted: Nanjing First Hospital, Nanjing Medical University, Vonoprazan + Amoxicillin (NCT06340724)
- 2024-02-29Phase 3 first posted: Il-Yang Pharm. Co., Ltd., Ilaprazole + Lansoprazole (NCT06284876)
- 2024-01-30Results posted on the registry: Providence Health & Services, Cyclophosphamide + Indomethacin (NCT02950259)
- 2023-12-08Phase 3 first posted: Alexandria University, Vonoprazan + Amoxicillin (NCT06162949)
- 2023-11-01Results posted on the registry: Cinclus Pharma Holding AB, X842 + X842 Dummy (NCT05055128)
- 2023-05-12Phase 3 first posted: TenNor Therapeutics (Suzhou) Limited, Rifasutenizol capsules + Rabeprazole sodium enteric-coated tablets (NCT05857163)
- 2023-03-03Phase 3 first posted: Biao Zou, FMT + Conventional drugs (NCT05753774)
- 2023-01-11Phase 3 first posted: Aya Mohamed Sadek Elsaid, Omeprazole (NCT05680870)
- 2022-12-12Phase 3 first posted: Hoffmann-La Roche, Inavolisib + Fulvestrant (NCT05646862)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision